NYSE: ZTSZoetis Inc Stock
$173.28+4.41 (+2.61%)
Updated May 15, 2024
ZTS Price
$173.28
Fair Value Price
N/A
Market Cap
$79.07B
52 Week Low
$144.80
52 Week High
$201.92
P/E
33.39x
P/B
15.63x
P/S
8.87x
PEG
2.78x
Dividend Yield
0.93%
Revenue
$8.73B
Earnings
$2.39B
Gross Margin
70%
Operating Margin
36.9%
Profit Margin
27.4%
Debt to Equity
1.84
Operating Cash Flow
$2B
Beta
0.94
Next Earnings
May 22, 2024
Ex-Dividend
Apr 18, 2024
Next Dividend
Jun 4, 2024
ZTS Overview
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the U.S. and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines. . The company was founded in 1952. It was spun off from Pfizer in 2013/06 and is now an independent company. Zoetis headquartered in Parsippany, NJ.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ZTS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ZTS ($173.28) is trading above its intrinsic value of $50.27, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ZTS is poor value based on its earnings relative to its share price (33.39x), compared to the US market average (31.36x)
P/E vs Market Valuation
ZTS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more ZTS due diligence checks available for Premium users.
Be the first to know about important ZTS news, forecast changes, insider trades & much more!
ZTS News
Valuation
ZTS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
33.39x
Industry
-1.36x
Market
31.36x
ZTS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ZTS is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
ZTS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
15.63x
Industry
2.21x
ZTS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ZTS price to earnings growth (PEG)
For valuing profitable companies with growth potential
ZTS is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
ZTS's financial health
Profit margin
Revenue
$2.2B
Net Income
$599.0M
Profit Margin
27.4%
ZTS's Earnings (EBIT) of $3.22B... subscribe to Premium to read more.
Interest Coverage Financials
ZTS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$14.3B
Liabilities
$9.3B
Debt to equity
1.84
ZTS's short-term assets ($6.36B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ZTS's long-term liabilities ($7.39B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ZTS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ZTS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$595.0M
Investing
-$131.0M
Financing
-$524.0M
ZTS's operating cash flow ($2.40B)... subscribe to Premium to read more.
Debt Coverage Financials
ZTS vs Pharmaceutical Stocks
Zoetis Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.